Patents by Inventor Robert Anthony Galemmo, Jr.

Robert Anthony Galemmo, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LSD1 inhibitors
    Patent number: 10233152
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 19, 2019
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, Jr.
  • LSD1 Inhibitors
    Publication number: 20180127369
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: October 5, 2017
    Publication date: May 10, 2018
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, JR.
  • LSD1 inhibitors
    Patent number: 9809541
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: November 7, 2017
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, Jr.
  • LSD1 Inhibitors
    Publication number: 20170183308
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 3, 2016
    Publication date: June 29, 2017
    Applicant: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, JR.
  • 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
    Patent number: 6750225
    Abstract: The present application describes 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones of the following formula or pharmaceutically acceptable salt forms thereof: wherein ring Rb is 3-amido or 4-methoxy, Ra can be cyano, trifluoromethyl, or amido, and R can be a substituted phenyl, a substituted imidazolyl, or a substituted pyridine. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: June 15, 2004
    Assignee: Bristol-Myers Squibb Pharms Company
    Inventors: Donald Joseph Philip Pinto, Robert Anthony Galemmo, Jr., Michael James Orwat, Mimi Lifen Quan
  • N-(amidinophenyl)cyclourea analogs as factor Xa inhibitors
    Patent number: 6521614
    Abstract: The present application describes N-(amidinophenyl)cyclourea analogs of formula I: which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas Peter Maduskuie, Jr., Robert Anthony Galemmo, Jr., Celia Dominguez, Mimi Lifen Quan, Karen Anita Rossi, Petrus Fredericus Wilhelmus Stouten, Jung-Hui Sun, Brian Lloyd Wells
  • Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
    Patent number: 6060462
    Abstract: This invention relates to electrophilic dipeptide analogs conjugated to an N,N-disubstituted .alpha.-amino acid as inhibitors of trypsin-like serine protease enzymes.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: May 9, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert Anthony Galemmo, Jr., Matthew Mark Abelman, Eugene Cruz Amparo, John Matthew Fevig, Robert Madara Knabb, William Henry Miller, Gregory James Pacofsky, Patricia Carol Weber, Joseph Cacciola
  • Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
    Patent number: 5939418
    Abstract: Isoxazolines, isothiazolines and pyrazolines which are inhibitors of Factor Xa, pharmaceutical compositions containing these compounds, and methods of using these compounds as anticoagulant agents for treatment and prevention of thromboembolic disorders. The compounds can be represented by the formula: ##STR1## where X is O, S or NR.sup.15.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: August 17, 1999
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Mimi Lifen Quan, John Wityak, Robert Anthony Galemmo, Jr., Petrus F. W. Stouten, James Russell Pruitt, Donald J. P. Pinto
  • N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
    Patent number: 5925635
    Abstract: The present application describes N-(amidinophenyl)cyclourea analogs of formula I: ##STR1## which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: July 20, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Thomas Peter Maduskuie, Jr., Robert Anthony Galemmo, Jr., Celia Dominguez, Mimi Lifen Quan, Karen Anita Rossi, Petrus Fredericus Wilhelmus Stouten, Jung-Hui Sun, Brian Lloyd Wells